Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
P/E ratio for Pharma Mar, S.A. (PHM.MC)
P/E ratio as of 2023: 664.68
According to Pharma Mar, S.A.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 664.68. At the end of 2022 the company had a P/E ratio of 23.52.
P/E ratio history for Pharma Mar, S.A. from 2002 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | 664.68 |
| 2022 | 23.52 |
| 2021 | 11.10 |
| 2020 | 9.46 |
| 2019 | -86.04 |
| 2018 | -43.51 |
| 2017 | -21.21 |
| 2016 | -24.82 |
| 2015 | 84.04 |
| 2014 | 44.76 |
| 2013 | 44.96 |
| 2012 | 40.69 |
| 2011 | -276.29 |
| 2010 | -49.38 |
| 2009 | -29.97 |
| 2008 | -16.39 |
| 2007 | -27.02 |
| 2006 | -24.39 |
| 2005 | 28503.02 |
| 2004 | 795.55 |
| 2003 | -42.86 |
| 2002 | -30.86 |